Emergent BioSolutions Inc. revised earnings guidance for the full year of 2018. The company now expects total revenue to be in the range of $779 million - $784 million compared to previous guidance of total revenue to be in the range of $770 million - $800 million, net income to be in the range of $60 million - $64 million compared to previous guidance of net income to be in the range of $60 million - $70 million, pretax income to be in the range of $79 million - $83 million compared to previous guidance of pretax income to be in the range of $75 million - $90 million and EBITDA to be in the range of $152 million - $156 million compared to previous guidance of EBITDA to be in the range of $155 million - $165 million.

For the first quarter of 2019, the company anticipates total revenues of $185 million to $205 million.

For 2019, the company expects total revenues to be in the range of $1,060 million - $1,140 million, net income to be in the range of $80 million - $110 million and EBITDA to be in the range of $150 million - $180 million.